![Hiroaki Shizuya](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hiroaki Shizuya
Founder at Aliva Biopharmaceuticals, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gary S. Lazar | M | - |
Aliva Biopharmaceuticals, Inc.
![]() Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Manish Singh | M | 56 |
Aliva Biopharmaceuticals, Inc.
![]() Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | 1 years |
Larry L. Green | M | - |
Aliva Biopharmaceuticals, Inc.
![]() Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 3 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hiroaki Shizuya
- Personal Network